These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 36284838)

  • 1. Current and future perspectives of chimeric antigen receptors against glioblastoma.
    Zhang J; Siller-Farfán JA
    Immunother Adv; 2022; 2(1):ltac014. PubMed ID: 36284838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current progress in chimeric antigen receptor T cell therapy for glioblastoma multiforme.
    Marei HE; Althani A; Afifi N; Hasan A; Caceci T; Pozzoli G; Cenciarelli C
    Cancer Med; 2021 Aug; 10(15):5019-5030. PubMed ID: 34145792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of genetic modifiers enhancing B7-H3-targeting CAR T cell therapy against glioblastoma through large-scale CRISPRi screening.
    Li X; Sun S; Zhang W; Liang Z; Fang Y; Sun T; Wan Y; Ma X; Zhang S; Xu Y; Tian R
    J Exp Clin Cancer Res; 2024 Apr; 43(1):95. PubMed ID: 38561797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CAR-T Therapy for Pediatric High-Grade Gliomas: Peculiarities, Current Investigations and Future Strategies.
    Antonucci L; Canciani G; Mastronuzzi A; Carai A; Del Baldo G; Del Bufalo F
    Front Immunol; 2022; 13():867154. PubMed ID: 35603195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tandem CAR-T cells targeting CD70 and B7-H3 exhibit potent preclinical activity against multiple solid tumors.
    Yang M; Tang X; Zhang Z; Gu L; Wei H; Zhao S; Zhong K; Mu M; Huang C; Jiang C; Xu J; Guo G; Zhou L; Tong A
    Theranostics; 2020; 10(17):7622-7634. PubMed ID: 32685008
    [No Abstract]   [Full Text] [Related]  

  • 6. Challenges in the Treatment of Glioblastoma by Chimeric Antigen Receptor T-Cell Immunotherapy and Possible Solutions.
    Zhang P; Zhang Y; Ji N
    Front Immunol; 2022; 13():927132. PubMed ID: 35874698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CAR T Cell-Based Immunotherapy for the Treatment of Glioblastoma.
    Maggs L; Cattaneo G; Dal AE; Moghaddam AS; Ferrone S
    Front Neurosci; 2021; 15():662064. PubMed ID: 34113233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CAR T Cell Therapy in Primary Brain Tumors: Current Investigations and the Future.
    Lin YJ; Mashouf LA; Lim M
    Front Immunol; 2022; 13():817296. PubMed ID: 35265074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The update of chimeric antigen receptor-T cells therapy in glioblastoma.
    Chou CJ; Lin CF; Chen YW; Huang PI; Yang YP; Wang ML; Hung KF; Lee YY
    J Chin Med Assoc; 2020 May; 83(5):442-445. PubMed ID: 32217989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chimeric Antigen Receptor T Cells for Glioblastoma: Current Concepts, Challenges, and Future Perspectives.
    Karschnia P; Teske N; Thon N; Subklewe M; Tonn JC; Dietrich J; von Baumgarten L
    Neurology; 2021 Aug; 97(5):218-230. PubMed ID: 33986138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Updates On Chimeric Antigen Receptor-Mediated Glioblastoma Immunotherapy.
    Mao G; Sampath P; Sengupta S
    R I Med J (2013); 2017 Jun; 100(6):39-42. PubMed ID: 28564668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival.
    Genßler S; Burger MC; Zhang C; Oelsner S; Mildenberger I; Wagner M; Steinbach JP; Wels WS
    Oncoimmunology; 2016 Apr; 5(4):e1119354. PubMed ID: 27141401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor efficacy of chimeric antigen receptor T cells against EGFRvIII-expressing glioblastoma in C57BL/6 mice.
    Chen M; Sun R; Shi B; Wang Y; Di S; Luo H; Sun Y; Li Z; Zhou M; Jiang H
    Biomed Pharmacother; 2019 May; 113():108734. PubMed ID: 30849636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Engineered CAR-T and novel CAR-based therapies to fight the immune evasion of glioblastoma: gutta cavat lapidem.
    Gatto L; Franceschi E; Di Nunno V; Maggio I; Lodi R; Brandes AA
    Expert Rev Anticancer Ther; 2021 Dec; 21(12):1333-1353. PubMed ID: 34734551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using chimeric antigen receptor T-cell therapy to fight glioblastoma multiforme: past, present and future developments.
    Soler DC; Kerstetter-Fogle A; McCormick TS; Sloan AE
    J Neurooncol; 2022 Jan; 156(1):81-96. PubMed ID: 34825292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B7-H3 in Brain Malignancies: Immunology and Immunotherapy.
    Guo X; Chang M; Wang Y; Xing B; Ma W
    Int J Biol Sci; 2023; 19(12):3762-3780. PubMed ID: 37564196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chimeric Antigen Receptor (CAR) T Cell Therapy for Glioblastoma.
    Verma A; Rafiq S
    Cancer Treat Res; 2022; 183():161-184. PubMed ID: 35551659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
    Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
    Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transgenic Expression of IL15 Improves Antiglioma Activity of IL13Rα2-CAR T Cells but Results in Antigen Loss Variants.
    Krenciute G; Prinzing BL; Yi Z; Wu MF; Liu H; Dotti G; Balyasnikova IV; Gottschalk S
    Cancer Immunol Res; 2017 Jul; 5(7):571-581. PubMed ID: 28550091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proposing a tandem AND-gate CAR T cell targeting glioblastoma multiforme.
    Sabahi M; Jabbari P; Alizadeh Haghighi M; Soltani S; Soudi S; Rahmani F; Rezaei N
    Med Hypotheses; 2020 Apr; 137():109559. PubMed ID: 31962251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.